Jan 6 (Reuters) - Variant Bio, a private biotech firm, said on Tuesday it has launched a platform that uses artificial intelligence on genetic data to discover new ‌drug candidates to send into human ...

Curi Bio’s ribbon cutting in April 2025 for its new headquarters on Seattle’s waterfront. Elliot Fisher, co-founder and chief business officer, cuts the ribbon with a sword while CEO Nicholas Geisse ...

• Current Chief Legal Officer Yalonda Howze, JD named Interim CEO & President For more information, please visit www.generationbio.com. Forward-Looking StatementsAny statements in this press release ...

The new ingredient is positioned as an ‘insurance policy’ against cocoa supply chain volatility and says the bio-identical ingredient could stabilize supply as climate change strains traditional crops ...

Important genetic differences in how females and males experience depression have been revealed for the first time in findings that could pave the way for more targeted intervention and treatments.

Artificial intelligence can design toxins that evade security controls. A team at Microsoft says it used artificial intelligence to discover a "zero day" vulnerability in the biosecurity systems used ...

NASA on Monday introduced 10 new astronauts, four men and six women selected from more than 8,000 applicants, to begin training for future flights to the International Space Station, the moon and, ...

- Early pharma applications already underway through a research collaboration with a large pharma partner, validating Fauna Brain’s translational potential EMERYVILLE, Calif.--(BUSINESS WIRE)--Fauna ...

COLUMBUS, Ohio — Breana Albizu is an award-winning traffic anchor and journalist who joined 10TV in May 2025. You can find Breana giving the latest roadway updates on 10TV News This Morning from 4:25 ...

CSE Class 10th Chemistry Question Paper 2025: The ICSE Class 10th Chemistry 2025 was conducted on March 21, 2025, with the help of the Council for the Indian School Certificate Examinations (CISCE).

Flying high as one of the world’s premier developers of gene therapies in early 2018, bluebird bio’s share price hit a dizzying $2,300 apiece. But seven years later—after failing to build a market for ...